Loading…
Reported covered position: Constituent Services Advocate, Outreach Director, Legislative Assistant, Legislative Director and chief of Staff - Senator Amy Klobuchar
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Health Insurance Tax Relief Act of 2019
Client: AMERICA'S HEALTH INSURANCE PLANS (AHIP) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
H. R. 1398, the Health Insurance Tax Relief Act.
Health Insurance Tax Relief Act of 2019
Client: AMERICA'S HEALTH INSURANCE PLANS (AHIP) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
H. R. 1398, the Health Insurance Tax Relief Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills.
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. NOTE: NO HHS contacts were made by Rose Sullivan.
Source: Senate LDA
| NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION | 17 | 2015–2019 |
| BEST BUY CO INC | 16 | 2015–2019 |
| INTEL CORPORATION | 16 | 2015–2019 |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | 14 | 2015–2018 |
| UNUM GROUP | 14 | 2015–2019 |
| U. S. CENTER FOR SAFESPORT | 11 | 2017–2019 |
| GLENMARK PHARMACEUTICALS, INC., USA | 10 | 2017–2019 |
| AIRBNB | 9 | 2018–2019 |
| UNIVISION COMMUNICATIONS INC. | 9 | 2016–2018 |
| MILLER/WENHOLD CAP.STRATEGIES ON BEHALF OF TAXICAB,LIMOUSINE&PARATRANSIT ASSN | 8 | 2015–2017 |
| NUCLEAR ENERGY INSTITUTE (NEI) | 8 | 2015–2017 |
| T-MOBILE USA, INC. | 8 | 2018–2019 |
| TEVA PHARMACEUTICALS USA INC | 8 | 2017–2018 |
| ESSENTIAL MINERALS ASSOCIATION (FORMERLY REPORTING AS IMA-NA) | 7 | 2016–2017 |
| GLASSDOOR, INC. | 6 | 2015–2017 |
| GOOGLE, INC. ON BEHALF OF X | 6 | 2018–2019 |
| Mozilla Corporation | 6 | 2017–2018 |
| SLACK TECHNOLOGIES, INC. | 6 | 2016–2017 |
| CONSTELLATION ENERGY GENERATION, LLC, FORMERLY REPORTING AS EXELON CORPORATION | 5 | 2016–2017 |
| VEMO EDUCATION | 4 | 2019 |
| AMERICA'S HEALTH INSURANCE PLANS (AHIP) | 3 | 2019 |
| MERCHANT CUSTOMER EXCHANGE LLC ("MCX") | 3 | 2015 |
| RETAIL INDUSTRY LEADERS ASSOCIATION (RILA) | 3 | 2015 |
| CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) | 1 | 2019 |
| VOLVO CAR CORPORATION | 1 | 2017 |
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H. R. 6, SUPPORT for Patients and Communities Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: GLENMARK PHARMACEUTICALS, INC., USA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. H. R. 6 SUPPORT for Patients and Communities Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: GLENMARK PHARMACEUTICALS, INC., USA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: GLENMARK PHARMACEUTICALS, INC., USA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: GLENMARK PHARMACEUTICALS, INC., USA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
Cancer Drug Parity Act of 2019
Client: BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Cancer Drug Parity Act of 2019
Client: BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Cancer Drug Parity Act of 2019
Client: BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Cancer Drug Parity Act of 2019
Client: BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Protect Medical Innovation Act of 2019
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the repeal of the medical device excise tax, including S.692 and H. R. 2207, the Protect Medical Innovation Act of 2019.
Protect Medical Innovation Act of 2019
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the repeal of the medical device excise tax, including S.692 and H. R. 2207, the Protect Medical Innovation Act of 2019.
Protect Medical Innovation Act of 2019
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the repeal of the medical device excise tax, including S.692 and H. R. 2207, the Protect Medical Innovation Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CVS HEALTH · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the pharmacy benefit manager/pharmacy and insurance industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 1895 Lower Health Care Costs Act, S. 2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act. H. R. 3502, the Protecting People from Surprise Medical Bills Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CVS HEALTH · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the pharmacy benefit manager/pharmacy and insurance industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 1895 Lower Health Care Costs Act, S. 2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act. H. R. 3502, the Protecting People from Surprise Medical Bills Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CVS HEALTH · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the pharmacy benefit manager/pharmacy and insurance industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 1895 Lower Health Care Costs Act, S. 2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act. H. R. 3502, the Protecting People from Surprise Medical Bills Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Renewable Fuel Standard Integrity Act of 2019
Client: FUELS AMERICA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the Renewable Fuel Standard (RFS) including, small refinery waivers regulations on the annual renewable volume obligations, regulations regarding reid vapor pressure (RVP), and proposals to regulate renewable identification numbers (RINs). H. R. 3006, Renewable Fuel Standard Integrity Act of 2019 and S.1840, A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions, and for other purposes.
Renewable Fuel Standard Integrity Act of 2019
Client: FUELS AMERICA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the Renewable Fuel Standard (RFS) including, small refinery waivers, regulations regarding Reid vapor pressure (RVP), and proposals to regulate renewable identification numbers (RINs). H. R. 3006, Renewable Fuel Standard Integrity Act of 2019 and S.1840, A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
Renewable Fuel Standard Integrity Act of 2019
Client: FUELS AMERICA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the Renewable Fuel Standard (RFS) including, small refinery waivers regulations on the annual renewable volume obligations, regulations regarding reid vapor pressure (RVP), and proposals to regulate renewable identification numbers (RINs). H. R. 3006, Renewable Fuel Standard Integrity Act of 2019 and S.1840, A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions, and for other purposes.
Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019
Client: U. S. CENTER FOR SAFESPORT · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to funding for the U. S. Center for SafeSport, including S.2584 and H. R. 3055, FY 2020 Commerce, Justice, Science, and Related Agencies Appropriations Act.
Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019
Client: U. S. CENTER FOR SAFESPORT · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to funding for the U. S. Center for SafeSport, including S.2584 and H. R. 3055, FY 2020 Commerce, Justice, Science, and Related Agencies Appropriations Act.
Nogales Wastewater Fairness Act
Client: CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of H. R. 3204, the Drug Quality and Security Act.
Protecting People From Surprise Medical Bills Act
Client: CVS HEALTH · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the pharmacy benefit manager/pharmacy and insurance industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 1895 Lower Health Care Costs Act, S. 2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act. H. R. 3502, the Protecting People from Surprise Medical Bills Act.
Protecting People From Surprise Medical Bills Act
Client: AMERICA'S HEALTH INSURANCE PLANS (AHIP) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to surprise billing, including H. R. 3630, No Surprises Act and H. R. 3502, Protecting People from Surprise Medical Bills Act. Issues related to drug pricing. S. 1895, Lower Health Care Costs Act and other health care cost initiatives currently under consideration.
Protecting People From Surprise Medical Bills Act
Client: CVS HEALTH · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the pharmacy benefit manager/pharmacy and insurance industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 1895 Lower Health Care Costs Act, S. 2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act. H. R. 3502, the Protecting People from Surprise Medical Bills Act.
Protecting People From Surprise Medical Bills Act
Client: CVS HEALTH · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the pharmacy benefit manager/pharmacy and insurance industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 1895 Lower Health Care Costs Act, S. 2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act. H. R. 3502, the Protecting People from Surprise Medical Bills Act.
Protecting People From Surprise Medical Bills Act
Client: AMERICA'S HEALTH INSURANCE PLANS (AHIP) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to surprise billing, including H. R. 3502, Protecting People from Surprise Medical Bills Act. Issues related to drug pricing. S. 1895, Lower Health Care Costs Act and other health care cost initiatives currently under consideration.
No Surprises Act
Client: AMERICA'S HEALTH INSURANCE PLANS (AHIP) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to surprise billing, including H. R. 3630, No Surprises Act and H. R. 3502, Protecting People from Surprise Medical Bills Act. Issues related to drug pricing. S. 1895, Lower Health Care Costs Act and other health care cost initiatives currently under consideration.
Issues related to tourism and travel and the sharing economy. Issues related to privacy and platform liability. H. R. 4232, Protecting Local Authority and Neighborhoods (PLAN) Act.
Issues related to tourism and travel and the sharing economy. Issues related to privacy and platform liability. H. R. 4232, Protecting Local Authority and Neighborhoods (PLAN) Act.
American Dream and Promise Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H. R. 6, SUPPORT for Patients and Communities Act.
American Dream and Promise Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. H. R. 6 SUPPORT for Patients and Communities Act.
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS, INC., USA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019.
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS, INC., USA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H. R. 6, SUPPORT for Patients and Communities Act.
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS, INC., USA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
BLOCKING Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. H. R. 6 SUPPORT for Patients and Communities Act.
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS, INC., USA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
CREATES Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
CREATES Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
CREATES Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H. R. 6, SUPPORT for Patients and Communities Act.
CREATES Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act.
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. NOTE: No HHS Contacts were made by Rose Sullivan
CREATES Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act.
CREATES Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. H. R. 6 SUPPORT for Patients and Communities Act.
CREATES Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act.
General education about the pharmacy benefit manager/pharmacy industry, including spread pricing proposals and S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
CREATES Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
General education about the pharmacy benefit manager/pharmacy industry, including spread pricing proposals and S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
FAST Generics Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H. R. 6, SUPPORT for Patients and Communities Act.
FAST Generics Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
FAST Generics Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. H. R. 6 SUPPORT for Patients and Communities Act.
FAST Generics Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
FAST Generics Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
FAST Generics Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act.
FAST Generics Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act.
FAST Generics Act of 2019
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Prescription Pricing for the People Act of 2019
Client: CVS HEALTH · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
Prescription Pricing for the People Act of 2019
Client: CVS HEALTH · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the pharmacy benefit manager/pharmacy industry, including spread pricing proposals and S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
Prescription Pricing for the People Act of 2019
Client: CVS HEALTH · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the pharmacy benefit manager/pharmacy industry, including spread pricing proposals and S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
Client: FUELS AMERICA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the Renewable Fuel Standard (RFS) including, small refinery waivers, regulations regarding Reid vapor pressure (RVP), and proposals to regulate renewable identification numbers (RINs). H. R. 3006, Renewable Fuel Standard Integrity Act of 2019 and S.1840, A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
Client: FUELS AMERICA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the Renewable Fuel Standard (RFS) including, small refinery waivers regulations on the annual renewable volume obligations, regulations regarding reid vapor pressure (RVP), and proposals to regulate renewable identification numbers (RINs). H. R. 3006, Renewable Fuel Standard Integrity Act of 2019 and S.1840, A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions, and for other purposes.
A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
Client: FUELS AMERICA · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to the Renewable Fuel Standard (RFS) including, small refinery waivers regulations on the annual renewable volume obligations, regulations regarding reid vapor pressure (RVP), and proposals to regulate renewable identification numbers (RINs). H. R. 3006, Renewable Fuel Standard Integrity Act of 2019 and S.1840, A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions, and for other purposes.
Lower Health Care Costs Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act.
Lower Health Care Costs Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act.
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
Lower Health Care Costs Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
General education about the pharmacy benefit manager/pharmacy industry, including spread pricing proposals and S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
Lower Health Care Costs Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Lower Health Care Costs Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Issues related to a Medicare Part D out of pocket cap for beneficiaries, including a policy to smooth out-of-pocket costs.
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · 2A
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. NOTE: NO HHS contacts was made by Rose Sullivan.
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · 1A
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. NOTE: NO HHS Contacts were made by Rose Sullivan.
Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills.
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1409, the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CVS HEALTH via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · 1A
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. NOTE: NO HHS Contacts were made by Rose Sullivan
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. NOTE: No HHS Contacts were made by Rose Sullivan
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
CVS HEALTH via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
General education about the pharmacy benefit manager/pharmacy and insurance industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 1895 Lower Health Care Costs Act, S. 2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act. H. R. 3502, the Protecting People from Surprise Medical Bills Act.
General education about the pharmacy benefit manager/pharmacy industry, including spread pricing proposals and S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
VEMO EDUCATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Policies affecting expanding educational access to higher education. General education about income Share Agreements. S.21145, ISA Student Protection Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNUM GROUP via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Proposals to advance paid leave.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U. S. CENTER FOR SAFESPORT via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Issues related to funding for the U. S. Center for SafeSport, including S.2584 and H. R. 3055, FY 2020 Commerce, Justice, Science, and Related Agencies Appropriations Act.
General education and information about the U. S. Center for SafeSport. Issues related to funding for the U. S. Center for SafeSport. S.2330, Empowering Olympic and Amateur Athletes Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T-MOBILE USA, INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Issues related to the telecommunications policy including spectrum, competition, rural broadband and security.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
YAHOO MEDIA (FORMERLY REPORTING AS OATH INC AND VARIOUS SUBSIDIARIES) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
General representation including advertising, mobile applications, geolocation, privacy.
Education and training and workforce diversity issues.
Copyright and content moderation.
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Issues related to third party servicing of medical imaging devices. Issues related to the regulation of contrast agents and medical imaging indications. Issues related to cybersecurity related to medical devices. Issues related to focused ultrasound.
Issues related to global trade and the competitiveness.
Issues related to the repeal of the medical device excise tax, including S.692 and H. R. 2207, the Protect Medical Innovation Act of 2019.
GOOGLE, INC. ON BEHALF OF X via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
General information about issues related to privacy, artificial intelligence, data protection, competition and broadband technology.
Background on precision agriculture and environmental impacts.
GLENMARK PHARMACEUTICALS, INC., USA via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FUELS AMERICA via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Issues related to the Renewable Fuel Standard (RFS) including, small refinery waivers regulations on the annual renewable volume obligations, regulations regarding reid vapor pressure (RVP), and proposals to regulate renewable identification numbers (RINs). H. R. 3006, Renewable Fuel Standard Integrity Act of 2019 and S.1840, A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
FMC CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Provide general overview information on company's products and issues. S.483, Pesticide Registration Improvement Extension Act of 2018.
Annual appropriations for the U. S. Environmental Protection Agency.
Issues related to international trade and competitiveness, including tariffs.
BEST BUY CO. INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Issues related to telehealth and remote patient monitoring.
Issues related to STEM education and the role of teen tech centers in preparing students for jobs of the future.
Issues related to international trade and competitiveness, including tariffs.
ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
AIRBNB via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · 3A
Issues related to domestic and international travel and tourism and the sharing economy.
Issues related to tourism and travel.
Issues related to federal disaster recovery.
CVS HEALTH via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · fourth_quarter · Q4
General education about the pharmacy benefit manager/pharmacy and insurance industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 1895 Lower Health Care Costs Act, S. 2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act. H. R. 3502, the Protecting People from Surprise Medical Bills Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICA'S HEALTH INSURANCE PLANS (AHIP) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues impacting the health insurance industry.
Issues related to surprise billing, including H. R. 3630, No Surprises Act and H. R. 3502, Protecting People from Surprise Medical Bills Act. Issues related to drug pricing. S. 1895, Lower Health Care Costs Act and other health care cost initiatives currently under consideration.
Issues related to drug pricing. S.1895, Lower Health Care Costs Act.
INTEL CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues related to intellectual property protection and patent reform. Issues related to Standard Essential Patents.
Issues relating to prioritizing fundamental science, basic research and development, quantum computing and exascale computing.
Issues related to trade, customs and trade facilitation as they relate to the semi-conductor industry.
CVS HEALTH via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
General education about the pharmacy benefit manager/pharmacy industry, including spread pricing proposals and S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
General education about the pharmacy benefit manager/pharmacy and insurance industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 1895 Lower Health Care Costs Act, S. 2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act. H. R. 3502, the Protecting People from Surprise Medical Bills Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
VEMO EDUCATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Policies affecting expanding educational access to higher education. General education about income Share Agreements. S.21145, ISA Student Protection Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U. S. CENTER FOR SAFESPORT via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues related to funding for the U. S. Center for SafeSport, including S.2584 and H. R. 3055, FY 2020 Commerce, Justice, Science, and Related Agencies Appropriations Act.
General education and information about the U. S. Center for SafeSport. Issues related to funding for the U. S. Center for SafeSport. S.2330, Empowering Olympic and Amateur Athletes Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
BEST BUY CO. INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues related to STEM education and the role of teen tech centers in preparing students for jobs of the future.
Issues related to telehealth and remote patient monitoring.
Issues related to the implementation of The Tax Cuts and Jobs Act of 2017, including the Qualified Improvement Property (QIP) technical correction. Treatment of sales tax collection for online purchases and state implementation of South Dakota V. Wayfair.
AIRBNB via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues related to federal disaster recovery.
Issues related to domestic and international travel and tourism and the sharing economy.
Issues related to tourism and travel and the sharing economy. Issues related to privacy and platform liability. H. R. 4232, Protecting Local Authority and Neighborhoods (PLAN) Act.
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues related to the repeal of the medical device excise tax, including S.692 and H. R. 2207, the Protect Medical Innovation Act of 2019.
Issues related to third party servicing of medical imaging devices. Issues related to the regulation of contrast agents and medical imaging indications. Issues related to cybersecurity related to medical devices. Issues related to focused ultrasound.
Issues related to global trade and the competitiveness.
GLENMARK PHARMACEUTICALS, INC., USA via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills.
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
FMC CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Annual appropriations for the U. S. Environmental Protection Agency.
Issues related to international trade and competitiveness, including tariffs.
Provide general overview information on company's products and issues. S.483, Pesticide Registration Improvement Extension Act of 2018.
YAHOO MEDIA (FORMERLY REPORTING AS OATH INC AND VARIOUS SUBSIDIARIES) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
General representation including advertising, mobile applications, geolocation, privacy.
General representation including Internet privacy encryption and electronic commerce and issues related to online advertising and search, mobile applications, intellectual property, artificial intelligence, data security and data retention policies, copyright reform, section 230 liability.
Copyright and content moderation.
UNUM GROUP via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Proposals to advance paid leave.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T-MOBILE USA, INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues related to the telecommunications policy including spectrum, competition, rural broadband and security.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE, INC. ON BEHALF OF X via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
General information about issues related to privacy, artificial intelligence, data protection, competition and broadband technology.
Background on precision agriculture and environmental impacts.
FUELS AMERICA via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · third_quarter · Q3
Issues related to the Renewable Fuel Standard (RFS) including, small refinery waivers regulations on the annual renewable volume obligations, regulations regarding reid vapor pressure (RVP), and proposals to regulate renewable identification numbers (RINs). H. R. 3006, Renewable Fuel Standard Integrity Act of 2019 and S.1840, A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
YAHOO MEDIA (FORMERLY REPORTING AS OATH INC AND VARIOUS SUBSIDIARIES) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
General representation including Internet privacy encryption and electronic commerce and issues related to online advertising and search, mobile applications, intellectual property, artificial intelligence, data security and data retention policies, copyright reform, section 230 liability.
General representation including advertising, mobile applications, geolocation, privacy.
Copyright and content moderation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
YAHOO MEDIA (FORMERLY REPORTING AS OATH INC AND VARIOUS SUBSIDIARIES) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
General representation including Internet privacy encryption and electronic commerce and issues related to online advertising and search, mobile applications, intellectual property, artificial intelligence, data security and data retention policies, copyright reform, section 230 liability.
General representation including advertising, mobile applications, geolocation, privacy.
Copyright and content moderation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICA'S HEALTH INSURANCE PLANS (AHIP) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Issues impacting the health insurance industry.
Issues related to drug pricing. S.1895, Lower Health Care Costs Act.
H. R. 1398, the Health Insurance Tax Relief Act.
GLENMARK PHARMACEUTICALS, INC., USA via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CVS HEALTH via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act and S. 1895 Lower Health Care Costs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act.
Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015.
T-MOBILE USA, INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Issues related to the telecommunications policy including spectrum, competition, rural broadband and security.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
INTEL CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Issues related to intellectual property protection and patent reform. Issues related to Standard Essential Patents.
The development of smart, integrated systems and devices including the Internet of Things and Artificial Intelligence. Issues related to consumer privacy, 5G and autonomous vehicles. CPU security-related issues. Issues related to federal technology acquisition and use.
Issues relating to prioritizing fundamental science, basic research and development, quantum computing and exascale computing.
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Issues related to the repeal of the medical device excise tax, including S.692 and H. R. 2207, the Protect Medical Innovation Act of 2019.
Issues related to third party servicing of medical imaging devices. Issues related to the regulation of contrast agents and medical imaging indications. Issues related to cybersecurity related to medical devices.
Issues related to global trade and the competitiveness.
VEMO EDUCATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Policies affecting expanding educational access to higher education. General education about income Share Agreements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNUM GROUP via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Proposals to advance paid leave.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
FUELS AMERICA via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Issues related to the Renewable Fuel Standard (RFS) including, small refinery waivers, regulations regarding Reid vapor pressure (RVP), and proposals to regulate renewable identification numbers (RINs). H. R. 3006, Renewable Fuel Standard Integrity Act of 2019 and S.1840, A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
BEST BUY CO. INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Issues related to telehealth and remote patient monitoring.
Issues related to international trade and competitiveness, including tariffs.
Issues related to the implementation of The Tax Cuts and Jobs Act of 2017, including the Qualified Improvement Property (QIP) technical correction. Treatment of sales tax collection for online purchases and state implementation of South Dakota V. Wayfair, support for the extension of the Work Opportunity Tax Credit.
FMC CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Issues related to international trade and competitiveness, including tariffs.
Issues related to the Endangered Species Act.
Annual appropriations for the U. S. Environmental Protection Agency.
AIRBNB via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
Issues related to domestic and international travel and toursim and the sharing economy, and issues related to the West Bank.
Issues related to federal disaster recovery.
FY2020 funding provisions.
U. S. CENTER FOR SAFESPORT via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
General education and information about the U. S. Center for SafeSport. Issues related to funding for the U. S. Center for SafeSport.
Issues related to funding for the U. S. Center for SafeSport.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE, INC. ON BEHALF OF X via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · Q2
General information about issues related to privacy, artificial intelligence, data protection, competition and broadband technology.
VEMO EDUCATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · second_quarter · RR
Policies affecting expanding educational access to higher education.
YAHOO MEDIA (FORMERLY REPORTING AS OATH INC AND VARIOUS SUBSIDIARIES) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
General representation including Internet privacy encryption and electronic commerce and issues related to online advertising and search, mobile applications, intellectual property, artificial intelligence, data security and data retention policies.
General representation including advertising, electronic commerce, mobile applications, geolocation, privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CVS HEALTH via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act.
General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
INTEL CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
The development of smart, integrated systems and devices including the Internet of Things, Smart America and Artificial Intelligence. Issues related to consumer privacy, 5G and autonomous vehicles. CPU security-related issues. Issues related to federal technology acquisition and use.
Issues related to telemedicine and remote patient monitoring. Issues related to the implementation and adoption of health information technology, genomics and precision medicine. Issues related to Intel's Connected Care benefits and implications for the health care delivery system.
AIRBNB via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues related to tourism and travel and the sharing economy. Issues related to privacy and platform liability.
Issues related to domestic and international travel and toursim and the sharing economy, and issues related to the West Bank.
FY2020 funding provisions.
AMERICA'S HEALTH INSURANCE PLANS (AHIP) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues impacting the health insurance industry.
UNUM GROUP via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Proposals to advance paid leave.
Filing targets: SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues related to cybersecurity in medical devices.
Issues related to the repeal of the medical device excise tax, including S.692, the Protect Medical Innovation Act of 2019.
Issues related to service of medical devices. Issues related to the regulation of contrast agents and medical imaging indications. Issues related to cybersecurity related to medical devices. Issues related to third party servicing of medical imaging devices.
ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues related to global competitiveness of the generic and biosimilar industry including tariffs and trade policy, including the US, Mexico, Canada Agreement (USMCA).
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H. R. 6, SUPPORT for Patients and Communities Act.
CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of H. R. 3204, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1409, the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
GLENMARK PHARMACEUTICALS, INC., USA via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FUELS AMERICA via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues related to the Renewable Fuel Standard (RFS) including, small refinery waivers, regulations regarding Reid vapor pressure (RVP), and proposals to regulate renewable identification numbers (RINs).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEST BUY CO. INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues related to telehealth and remote patient monitoring.
Issues related to the implementation of The Tax Cuts and Jobs Act of 2017. Treatment of sales tax collection for online purchases and state implementation of South Dakota V. Wayfair.
Issues related to international trade and competitiveness including tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T-MOBILE USA, INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues related to the telecommunications policy including spectrum, competition, rural broadband and security.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U. S. CENTER FOR SAFESPORT via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
General education and information about the U. S. Center for SafeSport. Issues related to funding for the U. S. Center for SafeSport.
Issues related to funding for the U. S. Center for SafeSport.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE, INC. ON BEHALF OF X via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
General information about issues related to privacy, artificial intelligence, data protection, competition and broadband technology.
FMC CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2019 · first_quarter · Q1
Issues related to international trade and competitiveness, including tariffs.
Provide general overview information on company's products and issues. S.483, Pesticide Registration Improvement Extension Act of 2018.
Issues related to the Endangered Species Act.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, Treasury, Dept of
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Issues related to service of medical devices. Issues related to the regulation of contrast agents and medical imaging indications. Issues related to cybersecurity related to medical devices. Issues related to H. R. 2118, the Medical Device Servicing Safety and Accountability Act. Issues related to H. R. 2009, the Fostering Innovation in Medical Imaging Act of 2017.
Issues related to the repeal of the medical device excise tax including S.108, the Medical Device Access and Innovation Protection Act and H. R. 184, the Protect Medical Innovation Act of 2017, and H. R.4617.
BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Issues related to blood cancer research funding included in the FY 2019 Labor-HHS and Department of Defense Appropriations Bills.
Issues related to Medicare Part D as related to blood cancer beneficiaries.
CVS HEALTH via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
General education about the pharmacy benefit manager/pharmacy industry, including S.637, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.974 and H. R. 2212, The CREATES Act. Proactive measures to curb opioid abuse, including H. R. 3528, Every Prescription Conveyed Securely Act, and H. R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018, as well as H.R. 6, the SUPPORT for Patients and Communities Act.
General education about the pharmacy benefit manager/pharmacy industry, including S.637, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to access and affordability of health care for veterans. Issues related to the proposed CVS-Aetna merger. Legislative efforts to address the opioid epidemic, including H. R. 3528, Every Prescription Conveyed Securely Act, and H. R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018, as well as H.R. 6, the SUPPORT for Patients and Communities Act.
BEST BUY CO. INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Issues related to comprehensive tax reform. Treatment of sales tax collection for online purchases, including S. 976, The Marketplace Fairness Act of 2017 and H. R. 2193, The Remote Transactions Parity Act of 2017.
Issues related to international trade and competitiveness including tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Issues related to Federal Aviation Administration small unmanned aerial systems/UAS registration rules and UAS petitions.
Innovation and competitive issues as they affect the semi-conductor industry, spectrum policy, privacy and cybersecurity. Issues relating to prioritizing fundamental science, basic research and development and exascale computing.
Issues related to telemedicine and remote patient monitoring. Issues related to the implementation and adoption of health information technology, genomics and precision medicine. H. R. 5062, Advancing Access to Precision Medicine Act.
ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015.
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 2212 and S. 974, the CREATES Act of 2017, and H.R. 2051, the Fair Access for Safe and Timely Generics (FAST) Generics Act of 2017. H.R. 6. SUPPORT for Patients and Communities Act.
Issues related to global competitiveness of the generic and biosimilar industry including tariffs and trade policy, including the US, Mexico, Canada Agreement (USMCA).
FMC CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Issues related to the Endangered Species Act.
Provide general overview information on company's products and issues. H. R. 1029, the Pesticide Registration Improvement Extension Act of 2017. H.R. 2, The Agriculture and Nutrition Act of 2018. S. 3042, The Agriculture Improvement Act of 2018.
Issues related to international trade and competitiveness, including tariffs, Miscellaneous Tariff Bill (MTB) and Generalized System of Preferences (GSP).
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
GOOGLE, INC. ON BEHALF OF X via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
General information about issues related to privacy, artificial intelligence, data protection, competition and broadband technology.
AIRBNB via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Issues related to tourism and travel and the sharing economy. Issues related to privacy and platform liability.
Issues related to travel and tourism and the sharing economy.
Issues related to federal disaster recovery.
UNUM GROUP via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Proposal to enhance income protection for workers. A proposal to modify auto-enrollment treatment under the Employee Retirement Income Security Act of 1974.
Filing targets: SENATE
T-MOBILE USA, INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Issues related to the telecommunications policy including spectrum, competition, rural broadband and security.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U. S. CENTER FOR SAFESPORT via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Issues related to funding for the U. S. Center for SafeSport.
General education and information about the U.S. Center for SafeSport. Issues related to funding for the U. S. Center for SafeSport.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
YAHOO MEDIA (FORMERLY REPORTING AS OATH INC AND VARIOUS SUBSIDIARIES) via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
General representation including advertising, electronic commerce, mobile applications, geolocation, privacy.
General representation including Internet privacy encryption and electronic commerce and issues related to online advertising and search and data breach.
General representation including Internet privacy encryption and electronic commerce and issues related to online advertising and search, mobile applications, intellectual property, data security and data retention policies. Issues related to the Electronic Communications Privacy Act. And H. R. 387, the Email Protection Act. Issues related to artificial intelligence.
MOZILLA CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Issues related to open internet and consumer data privacy. Issues related to artificial intelligence and algorithms. Issues related to platform liability.
Issues related to antitrust in the technology sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FUELS AMERICA via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · Q4
Issues related to the Renewable Fuel Standard (RFS) including point of obligation, proposals to cap renewable identification number (RIN)s, proposals change octane standards, and H. R. 5212/S.2519 - the GREENER Fuels Act and S.517 - Consumer and Fuel Retailer Choice Act, and discussion draft H.R. _ the 21st Century Transportation Fuels Act.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · fourth_quarter · 4T
Tax proposals relating to the medical device excise tax including H. R. 184, the Protect Medical Innovation Act of 2017, and S.108, the Medical Device Access and Innovation Protection Act and H. R. 4617.
Reimbursement for medical devices. Issues related to breakthrough pathways for the approval and coverage of medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
YAHOO MEDIA (FORMERLY REPORTING AS OATH INC AND VARIOUS SUBSIDIARIES) via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
General representation including Internet privacy encryption and electronic commerce and issues related to online advertising and search, mobile applications, intellectual property, data security and data retention policies. Issues related to the Electronic Communications Privacy Act. And H. R. 387, the Email Protection Act. Issues related to artificial intelligence.
General representation including Internet privacy encryption and electronic commerce and issues related to online advertising and search and data breach.
INTEL CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
Issues related to the Intel Capital Diversity Initiative, which invests in businesses founded and/or managed by women, under-represented minorities, U. S. military veterans, the physically disabled, and the LGBTQ community.
Issues related to telemedicine and remote patient monitoring. Issues related to the implementation and adoption of health information technology, genomics and precision medicine. H. R. 5062, Advancing Access to Precision Medicine Act.
The development of smart, integrated systems and devices including the Internet of Things, Smart America and Artificial Intelligence. H. R. 1576, the Innovation Corps Act of 2017. Issues related to 5G. Issues related to autonomous vehicles. S.1885, AV START Act and H. R. 3388 SELF DRIVE Act. CPU security-related issues. Issues related to federal technology acquisition and use. H. R. 4953/S.1682 AIRWAVES Act. Issues related to data privacy.
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
Issues related to global trade and the competitiveness including the China 301 action.
Issues related to VA acquisition of medical imaging technology including supply chain and Potential Effects of Kingdomware decision on High Tech Medical Imaging Equipment (HTME) purchases.
Issues related to service of medical devices. Issues related to the regulation of contrast agents and medical imaging indications. Issues related to cybersecurity related to medical devices. Issues related to H. R. 2118, the Medical Device Servicing Safety and Accountability Act. Issues related to H. R. 2009, the Fostering Innovation in Medical Imaging Act of 2017.
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
Issues related to international trade and global competitiveness including H. R. 4311/S.2098 the Foreign Investment Risk Review Modernization Act of 2017 (FIRRMA) and tariffs.
Reimbursement for medical devices. Issues related to breakthrough pathways for the approval and coverage of medical devices.
Tax proposals relating to the medical device excise tax including H. R. 184, the Protect Medical Innovation Act of 2017, and S.108, the Medical Device Access and Innovation Protection Act and H. R. 4617.
AIRBNB via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
Issues related to travel and tourism and the sharing economy.
Issues related to federal disaster recovery.
Issues related to tourism and travel and the sharing economy. Issues related to privacy and platform liability.
FMC CORPORATION via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
Provide general overview information on company's products and issues. H. R. 1029, the Pesticide Registration Improvement Extension Act of 2017. H.R. 2, The Agriculture and Nutrition Act of 2018. S. 3042, The Agriculture Improvement Act of 2018.
Issues related to international trade and competitiveness, including tariffs, Miscellaneous Tariff Bill (MTB) and Generalized System of Preferences (GSP).
Issues related to the Endangered Species Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CVS HEALTH via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
General education about the pharmacy benefit manager/pharmacy industry, including S.637, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to access and affordability of health care for veterans. Issues related to the proposed CVS-Aetna merger. Legislative efforts to address the opioid epidemic, including H. R. 3528, Every Prescription Conveyed Securely Act, and H. R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018, as well as H.R. 6, the SUPPORT for Patients and Communities Act.
General education about the pharmacy benefit manager/pharmacy industry, including S.637, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.974 and H. R. 2212, The CREATES Act. Proactive measures to curb opioid abuse, including H. R. 3528, Every Prescription Conveyed Securely Act, and H. R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018, as well as H.R. 6, the SUPPORT for Patients and Communities Act.
ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 2212 and S.974, the CREATES Act of 2017, and H. R. 2051, the Fair Access for Safe and Timely Generics (FAST) Generics Act of 2017. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H.R. 6, SUPPORT for Patients and Communities Act.
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 2212 and S. 974, the CREATES Act of 2017, and H.R. 2051, the Fair Access for Safe and Timely Generics (FAST) Generics Act of 2017. H.R. 6. SUPPORT for Patients and Communities Act.
T-MOBILE USA, INC. via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
Issues related to the telecommunications policy including spectrum, competition, rural broadband and security.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U. S. CENTER FOR SAFESPORT via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
General education and information about the U.S. Center for SafeSport. Issues related to funding for the U. S. Center for SafeSport. H. R. 1625, Consolidated Appropriations Act 2018. Public Law 115-141.
Issues related to funding for the U. S. Center for SafeSport. H. R. 1625, Consolidated Appropriations Act, 2018. Public Law 115-141.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act, and it's Senate companion S.292, the Childhood Cancer Survivorship, Treatment Access, and Research Act of 2018. Issues related to Health Savings Accounts. Issues related to Short-Term Limited Duration health insurance plans.
GOOGLE, INC. ON BEHALF OF X via KOUNTOUPES DENHAM CARR & REID, LLC
2018 · third_quarter · Q3
General information about issues related to privacy, artificial intelligence, data protection, competition and broadband technology.
General representation including Internet privacy encryption and electronic commerce and issues related to online advertising and search, mobile applications, intellectual property, artificial intelligence, data security and data retention policies, copyright reform, section 230 liability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to VA use of device alternatives to opioids and FY 2020 Military Construction VA Appropriations Bill.
General education about medical imaging technology and issues related to VA use of device alternatives to opioids, FY2020 Military Construction VA Appropriations Legislation.
Issues related to cybersecurity in medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the Endangered Species Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the implementation of The Tax Cuts and Jobs Act of 2017, including the Qualified Improvement Property (QIP) technical correction. Treatment of sales tax collection for online purchases and state implementation of South Dakota V. Wayfair.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Issues related to global competitiveness of the generic and biosimilar industry including tariffs and trade policy, including the US, Mexico, Canada Agreement (USMCA).
Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to tourism and travel and the sharing economy. Issues related to privacy and platform liability. H. R. 4232, Protecting Local Authority and Neighborhoods (PLAN) Act.
FY2020 funding provisions.
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
H. R. 1398, the Health Insurance Tax Relief Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Innovation and competitive issues as they affect the semi-conductor industry, spectrum policy, privacy and cybersecurity. Issues relating to prioritizing fundamental science, basic research and development and exascale computing.
The development of smart, integrated systems and devices including the Internet of Things and Artificial Intelligence. Issues related to consumer privacy, 5G and autonomous vehicles. CPU security-related issues. Issues related to federal technology acquisition and use.
Issues related to the application of Artificial Intelligence in health care. Issues related to the implementation and adoption of health information technology, genomics and precision medicine.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Issues related to global competitiveness of the generic and biosimilar industry including tariffs and trade policy, including the US, Mexico, Canada Agreement (USMCA).
Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015.
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S.1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3, The Lower Drug Costs Now Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to international trade and competitiveness, including tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FY2020 funding provisions.
Issues related to tourism and travel.
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
Issues related to cybersecurity in medical devices.
General education about medical imaging technology and issues related to VA use of device alternatives to opioids, FY2020 Military Construction VA Appropriations Legislation.
Issues related to VA use of device alternatives to opioids and FY 2020 Military Construction VA Appropriations Bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to a Medicare Part D out of pocket cap for beneficiaries, including a policy to smooth out-of-pocket costs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Endangered Species Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Education and training and workforce diversity issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to surprise billing, including H. R. 3502, Protecting People from Surprise Medical Bills Act. Issues related to drug pricing. S. 1895, Lower Health Care Costs Act and other health care cost initiatives currently under consideration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act.
Issues related to global competitiveness of the generic and biosimilar industry including tariffs and trade policy, including the US, Mexico, Canada Agreement (USMCA).
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. S. 1895, the Lower Health Care Costs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Innovation and competitive issues as they affect the semi-conductor industry, spectrum policy, privacy and cybersecurity. Issues relating to prioritizing fundamental science, basic research and development and exascale computing.
Issues related to trade, customs and trade facilitation as they relate to the semi-conductor industry.
Issues related to telemedicine and remote patient monitoring. Issues related to the implementation and adoption of health information technology, genomics and precision medicine. Issues related to Intel's Connected Care benefits and implications for the health care delivery system. Issues related to the application of Artificial Intelligence in health care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to VA use of device alternatives to opioids and FY 2020 Military Construction VA Appropriations Bill.
General education about medical imaging technology and issues related to VA use of device alternatives to opioids, FY2020 Military Construction VA Appropriations Legislation.
Issues related to cybersecurity in medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to STEM education and the role of teen tech centers in preparing students for jobs of the future.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Provide general overview information on company's products and issues. S.483, Pesticide Registration Improvement Extension Act of 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tourism and travel.
Issues related to tourism and travel and the sharing economy. Issues related to privacy and platform liability.
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
Issues related to trade, customs and trade facilitation as they relate to the semi-conductor industry, the Committee on Foreign Investment in the United States (CFIUS), and import and export control systems.
Issues relating to prioritizing fundamental science, basic research and development, quantum computing and exascale computing.
Innovation and competitive issues as they affect the semi-conductor industry, spectrum policy, privacy and cybersecurity. Issues relating to prioritizing fundamental science, basic research and development and exascale computing.
Issues related to intellectual property protection and patent reform. Issues related to Standard Essential Patents.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tourism and travel.
Issues related to federal disaster recovery.
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
Issues related to global trade and the competitiveness.
General education about medical imaging technology and issues related to VA use of device alternatives to opioids.
Issues related to the FY 2020 VA Appropriations Bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015.
General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including H. R. 965 and S. 340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019, H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. H. R. 6 SUPPORT for Patients and Communities Act.
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to VA acquisition of medical imaging technology including supply chain and Potential Effects of Kingdomware decision on High Tech Medical Imaging Equipment (HTME) purchases.
Issues related to global trade and the competitiveness including the China 301 action.
Issues related to cybersecurity in medical devices.
Issues related to the affordability and availability of Helium for use by the medical imaging manufacturing community.
Filing targets: Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act, and it's Senate companion S.292, the Childhood Cancer Survivorship, Treatment Access, and Research Act of 2018. Issues related to Health Savings Accounts. Issues related to Short-Term Limited Duration health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Issues relating to prioritizing fundamental science, basic research and development, quantum computing and exascale computing. S.3143 and H. R. 6227, the National Quantum Initiative Act.
Issues related to trade, customs and trade facilitation as they relate to the semi-conductor industry, the Committee on Foreign Investment in the United States (CFIUS), and import and export control systems.
The development of smart, integrated systems and devices including the Internet of Things, Smart America and Artificial Intelligence. H. R. 1576, the Innovation Corps Act of 2017. Issues related to 5G. Issues related to privacy. Issues related to autonomous vehicles. S.1885, AV START Act and H. R. 3388 SELF DRIVE Act. CPU security-related issues. Issues related to federal technology acquisition and use. H. R. 4953/S.1682 AIRWAVES Act. Issues related to data privacy.
Issues related to intellectual property protection and patent reform. Issues related to Standard Essential Patents.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter parties review (IPR) process.
Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 2212 and S.974, the CREATES Act of 2017, and H. R. 2051, the Fair Access for Safe and Timely Generics (FAST) Generics Act of 2017. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H.R. 6, SUPPORT for Patients and Communities Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
Issues related to tourism and travel.
Filing targets: Federal Emergency Management Agency (FEMA), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General representation including advertising, electronic commerce, mobile applications, geolocation, privacy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to intellectual property protection and patent reform. Issues related to Standard Essential Patents.
Innovation and competitive issues as they affect the semi-conductor industry, spectrum policy and cybersecurity. Issues relating to prioritizing fundamental science, basic research and development and exascale computing.
Issues related to trade, customs and trade facilitation as they relate to the semi-conductor industry, the Committee on Foreign Investment in the United States (CFIUS), and import and export control systems.
Issues related to Federal Aviation Administration small unmanned aerial systems/UAS registration rules and UAS petitions.
Issues relating to prioritizing fundamental science, basic research and development, quantum computing and exascale computing. S.3143 and H. R. 6227, the National Quantum Initiative Act.
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
Issues related to cybersecurity in medical devices.
Issues related to the affordability and availability of Helium for use by the medical imaging manufacturing community.
Issues related to the repeal of the medical device excise tax including S.108, the Medical Device Access and Innovation Protection Act and H. R. 184, the Protect Medical Innovation Act of 2017, and H. R.4617.
Filing targets: Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE
Issues related to the VA procurement process.
Issues related to the role of medical devices and diagnostics including the regulation of lab developed tests, durable medical equipment, coverage and reimbursement for devices. Issues related to breakthrough pathways for the approval and coverage of medical devices. Issues related to the federal anti-kickback statute and the Stark Act, including medical device inspection review process. Issues related to post-market surveillance. Issues related to third party servicing of medical devices. And issues related to pain management and opiods.
Issues related to cyber security in medical device technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to policies that impact individuals with disabilities.
Issues related to tourism and travel.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter parties review (IPR) process.
Issues related to global competitiveness of the generic and biosimilar industry including tariffs and trade policy.
Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to blood cancer research funding included in the FY 2019 Labor-HHS and Department of Defense Appropriations Bills.
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE